Eli Lilly and Co. (LLY) just scored a major win in the world's second-largest pharmaceutical market. The company announced that Mounjaro, its once-weekly injectable diabetes treatment, will be added to China's state-run health insurance scheme starting January 1, 2026.

Access Expands, But So Does Competition

China's National Healthcare Security Administration made the decision official this past Sunday, putting Mounjaro on the national reimbursement list. That's great news for patients who'll now have easier access to the drug. The catch? Getting on China's insurance list typically means agreeing to lower prices in exchange for massive volume.

Mounjaro entered the Chinese market just this past January, years behind Novo Nordisk (NVO), whose similar diabetes drug Ozempic launched there in 2021. Novo Nordisk got Ozempic onto China's reimbursement list back in 2022, giving it a head start in the subsidized market.

Meanwhile, the competitive landscape is getting messy. Chinese drugmakers who previously churned out copycat weight-loss treatments for the U.S. market are now pivoting to produce generics of Novo Nordisk's Wegovy and Eli Lilly's Zepbound after the FDA tightened regulations. Last year alone, at least eight companies supplied raw ingredients for over a billion makeshift doses as demand exploded.

Mounjaro Powers Revenue Surge

The China insurance inclusion comes as Eli Lilly is crushing it globally with its diabetes portfolio. The company reported a 54% revenue jump in the third quarter of 2025, with Mounjaro and Zepbound leading the charge.

During the earnings call, Eli Lilly's international president Patrik Jonsson highlighted strong initial stocking of Mounjaro across major markets including China, Brazil, Mexico, and India. He noted that performance continued strengthening throughout the third quarter worldwide.

In December, the company also announced a price cut for Zepbound in the United States to boost patient accessibility. These strategic moves are expanding the drugs' reach while sharpening Eli Lilly's competitive position in what's becoming an increasingly crowded global market for diabetes and weight-loss treatments.